[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-436191-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-436191-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","advanced-hepatocellular-carcinoma-with-major-portal-vein-invasion-therapeutic-outcomes-of-hepatic-arterial-infusion-chemotherapy-vs-concurrent-radiotherapy","Advanced hepatocellular carcinoma with major portal vein invasion - Therapeutic outcomes of hepatic arterial infusion chemotherapy vs concurrent radiotherapy","","Hepatocellular carcinoma with major portal vein invasion causes very poor prognosis. This retrospective study compared therapeutic outcomes of a “new” hepatic artery infusion chemotherapy regimen with and without concurrent radiotherapy for patients with MPVI, both before and after propensity score matching. One hundred forty patients received HAIC alone and 35 received concurrent HAIC and radiotherapy. Response was assessed by mRECIST; progression-free and overall survival were estimated with Kaplan-Meier and Cox regression.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advanced-hepatocellular-carcinoma-with-major-portal-vein-invasion-therapeutic-outcomes-of-hepatic-arterial-infusion-chemotherapy-vs-concurrent-radiotherapy/436191/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advanced-hepatocellular-carcinoma-with-major-portal-vein-invasion-therapeutic-outcomes-of-hepatic-arterial-infusion-chemotherapy-vs-concurrent-radiotherapy/436191.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-09-30","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":26},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What was the purpose of comparing HAIC with and without concurrent radiotherapy?","Question",{"text":62,"@type":63},"To evaluate whether adding concurrent radiotherapy to a “new” HAIC regimen improves therapeutic outcomes for advanced HCC patients with major portal vein invasion.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How were objective response and survival outcomes assessed?",{"text":67,"@type":63},"Objective response rate was assessed using mRECIST, while progression-free survival and overall survival were calculated using Kaplan-Meier curves, followed by Cox regression for hazard ratios.",{"name":69,"@type":60,"acceptedAnswer":70},"What did the study find regarding overall survival before and after propensity score matching?",{"text":71,"@type":63},"In the initial cohort, the concurrent radiotherapy group showed higher ORR and PFS but shorter OS. After propensity score matching, the overall survival remained different between groups (reported as 10 vs 15 months).","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},436191,1790766468,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":26,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":110,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","J Chin MedAssoc  \nOriginal article  \nAdvanced hepatocellular carcinoma with major portal vein invasion: Therapeutic outcomes of hepatic arterial infusion chemotherapy vs concurrent radiotherapy  \nChia-Ling Chianga,b, Huei-Lung Lianga,b,* , Kuo-Chen Changc, Wei-Lun Tsaib,d, Hsien-Chung Yub,d, Kung-Hung Linb,d, Ming-Feng Lia,b  \naDepartment of Radiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC; bDepartment of Medical Imaging and Radiology, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan, ROC; cDepartment of Radiotherapy and Oncology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC; dDivision of Gastroenterology and Hepatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC  \nAbstract  \nBackground: Hepatocellular carcinoma (HCC) with major portal vein invasion (MPVI) presents very poor outcomes. Hepatic artery infusion chemotherapy (HAIC) and radiation therapy (RT) have both been found to be effective for advanced HCC. In this retrospective study, we compared the therapeutic outcomes of our “new” HAIC regimen with and without concurrent RT, before and after propensity score matching (PSM) in treating HCC patients with MPVI.  \nMethods: One hundred forty patients with MPVI received HAIC alone and 35 patients underwent concurrent HAIC and RT during a 16-year period. The left subclavian artery was adopted as the entry site for a temporary catheter placement for a 5-day chemoinfusion. The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) was adopted to assess the objective response rate (ORR) . The Kaplan-Meier curve was used to calculate progression-free survival (PFS) and overall survival (OS) between the two groups. Univariate and multivariate analyses by Cox regression model were used to assess hazard ratios.  \nResults: Of the 140 patients with Child-Pugh A liver function, the median OS was 17.0 months. In the initial cohort, higher ORRand PFS were found in the concurrent RT group than in the HAIC alone group (80% vs 66.4% and 9 vs 8 months, respectively) but shorter OS (10 .5 vs 14.5 months, p = 0.039) was observed. After PSM, the OS was 10 and 15 months (p = 0.012), respectively. Multivariable Cox regression analysis revealed that the significant factors for adjusting hazard ratios for OS were Child-Pugh classification, alpha fetal protein (AFP) level, and hepatic vein invasion.  \nConclusion: HAIC is an effective treatment for advanced HCC patients with MPVI. Concurrent HAIC and full-dose RT were associated with worse clinical outcomes.  \nKeywords: Hepatic artery; Hepatocellular carcinoma; Portal vein; Radiotherapy; Retrospective study  \n1. INTRODUCTION  \nHepatocellular carcinoma (HCC) is the fifth most common solid tumor and the third leading cause of cancer-related death globally.1 Portal vein invasion occurs in 35% to 50% of patients atthe time of diagnosis.1,2 Studies show that even under the best supportive care, HCC patients with major portal vein invasion (MPVI) have overall survival (OS) of \u003C4 months.2–4 Combined immuno-target therapy (atezolizumab and bevacizumab)5 has been recently recommended as the first-line therapy for advanced  \n* Address correspondence. Dr. Huei-Lung Liang, Department of Radiology, Kaohsiung Veterans General Hospital, 386 Dazhong 1st Road, Zuoying, Kaohsiung 813, Taiwan, [ROC. E-mail address: hlliang@vghks.gov.tw](ROC. E-mail address: hlliang@vghks.gov.tw) (H.-L. Liang). Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.  \nJournal of Chinese Medical Association. (2024) 87: 171-178.  \nReceived May 9, 2023; accepted December 3, 2023. doi: 10. 1097/JCMA.0000000000001040  \nCopyright © 2023, the Chinese Medical Association. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/](http://creativecommons.org/licenses/)[ ](http://creativecommons.org/licenses/","cbCais8dGK1TkGtN","https://ap.wps.com/l/cbCais8dGK1TkGtN","pdf",629356,"English","# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What was the purpose of comparing HAIC with and without concurrent radiotherapy?\",\"answer\":\"To evaluate whether adding concurrent radiotherapy to a “new” HAIC regimen improves therapeutic outcomes for advanced HCC patients with major portal vein invasion.\"},{\"question\":\"How were objective response and survival outcomes assessed?\",\"answer\":\"Objective response rate was assessed using mRECIST, while progression-free survival and overall survival were calculated using Kaplan-Meier curves, followed by Cox regression for hazard ratios.\"},{\"question\":\"What did the study find regarding overall survival before and after propensity score matching?\",\"answer\":\"In the initial cohort, the concurrent radiotherapy group showed higher ORR and PFS but shorter OS. After propensity score matching, the overall survival remained different between groups (reported as 10 vs 15 months).\"}]","Advanced hepatocellular carcinoma with major portal vein invasion - Therapeutic outcomes of hepatic arterial infusion chemotherapy vs concurrent radiotherapy | PDF",1790677090]